The Jiao Group

Year
Customize
179. Functional screening and rational design of compounds targeting GPR132 to treat diabetes. Jiale Wang, Xiaodong Dou, Jie Cheng, Jinpeng Sun*, Ning Jiao*, and Xiao Yu*. Nat Metab. 2023, 5, 1726–1746. Link
179. Functional screening and rational design of compounds targeting GPR132 to treat diabetes. Jiale Wang, Xiaodong Dou, Jie Cheng, Jinpeng Sun*, Ning Jiao*, and Xiao Yu*. Nat Metab. 2023, 5, 1726–1746.
178. Discovery of 3-oxo-1,2,3,4-tetrahydropyrido[1,2-a]pyrazin derivatives as SARS-CoV-2 main protease inhibitors through virtual screening and biological evaluation. X. Dou. Luhua Lai*, Ning Jiao*. Bioorg Med Chem Lett. 2024, 97, 129547. Link
178. Discovery of 3-oxo-1,2,3,4-tetrahydropyrido[1,2-a]pyrazin derivatives as SARS-CoV-2 main protease inhibitors through virtual screening and biological evaluation. X. Dou. Luhua Lai*, Ning Jiao*. Bioorg Med Chem Lett. 2024, 97, 129547.
172. Discovery of 2-(furan-2-ylmethylene)hydrazine-1-carbothioamide derivatives as novel inhibitors of SARS-CoV-2 main protease. X. Dou, Q Sun, G. Xu, S. Song, L. Zhang, Z. Liu, Luhua Lai*, and Ning Jiao*. Eur J Med Chem. 2022, 238, 114508. Link
172. Discovery of 2-(furan-2-ylmethylene)hydrazine-1-carbothioamide derivatives as novel inhibitors of SARS-CoV-2 main protease. X. Dou, Q Sun, G. Xu, S. Song, L. Zhang, Z. Liu, Luhua Lai*, and Ning Jiao*. Eur J Med Chem. 2022, 238, 114508.